Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
UT Southwestern Pioneers New Minimally Invasive Treatment for Prostate Cancer
12/13/2022
100th patient receives innovative MRI-guided ultrasound procedure to kill tumors with fewer side effects than surgery or radiation
100th patient receives innovative MRI-guided ultrasound procedure to kill tumors with fewer side effects than surgery or radiation
100th patient receives...
12/13/2022
IO Learning
News
Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
12/12/2022
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban.
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban.
Head-to-head observational...
12/12/2022
IO Learning

Advertisement

News
Exai Bio’s Non-invasive Blood-Based Platform Delivers Promising Data on Detecting Breast Cancer at its Earliest Stages
12/06/2022
Data from new study presented at the 2022 San Antonio Breast Cancer Symposium meaningfully builds on ground-breaking data presented at the 2021 Symposium
Data from new study presented at the 2022 San Antonio Breast Cancer Symposium meaningfully builds on ground-breaking data presented at the 2021 Symposium
Data from new study presented at...
12/06/2022
IO Learning
News
For Some Small Kidney Cancers, Freezing is More Effective Than Heat Treatment
11/29/2022
November 29, 2022 – For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of cancer-related...
November 29, 2022 – For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of cancer-related...
November 29,...
11/29/2022
IO Learning
News
Study Shows Promising Safety, Patient Outcomes Data for MRI-Guided Adaptive Radiation Therapy to Treat Pancreatic Cancer
11/21/2022
DETROIT (Nov. 21, 2022) – Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table...
DETROIT (Nov. 21, 2022) – Findings from a recent prospective study show promising safety and patient outcomes data for locally advanced and borderline resectable pancreatic cancer treatment using ablative Stereotactic MRI-Guided On-table...
DETROIT (Nov. 21, 2022) –...
11/21/2022
IO Learning

Advertisement

News
New Study Shows Recently Diagnosed Adult Cancer Survivors at Higher Risk for Bone Fractures
11/03/2022
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022 — Adult cancer survivors, particularly those diagnosed within five years and/or have a history of chemotherapy, have an increased risk for bone fractures, specifically pelvic and vertebral fractures, compared to...
ATLANTA, November 3, 2022...
11/03/2022
IO Learning
News
Disparities in Lung Cancer Detection: Moving Toward Equity & Inclusion
11/01/2022
Newswise — New Brunswick, N.J., November 1, 2022 – Communities, organizations and health professionals are taking action to improve inequalities in lung cancer detection. Anita Kinney, PhD, RN, FAAN, FABMR director of...
Newswise — New Brunswick, N.J., November 1, 2022 – Communities, organizations and health professionals are taking action to improve inequalities in lung cancer detection. Anita Kinney, PhD, RN, FAAN, FABMR director of...
Newswise — New Brunswick, N.J.,...
11/01/2022
IO Learning
News
Metastasis-Directed Radiation Therapy Plus Hormone Therapy Improves Progression-Free Survival for Men with Advanced Prostate Cancer
10/27/2022
MD Anderson presents results from Phase II EXTEND trial at ASTRO 2022 Newswise — Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to...
MD Anderson presents results from Phase II EXTEND trial at ASTRO 2022 Newswise — Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to...
MD Anderson presents results...
10/27/2022
IO Learning

Advertisement

News
Adding Radiation to Systemic Therapy Extends Overall Survival for Patients with Advanced Liver Cancer
10/24/2022
American Society for Radiation Oncolo...
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial...
10/24/2022
IO Learning
News
FLASH Radiation Therapy Shows Promise in First-in-Human Trial
10/23/2022
American Society for Radiation Oncolo...
American Society for Radiation Oncology (ASTRO) Ultra-high dose-rate radiation treatment found safe and effective for pain relief in small trial of patients with metastatic cancer SAN ANTONIO, October 23, 2022 – FLASH radiation...
American Society for Radiation Oncology (ASTRO) Ultra-high dose-rate radiation treatment found safe and effective for pain relief in small trial of patients with metastatic cancer SAN ANTONIO, October 23, 2022 – FLASH radiation...
American Society for Radiation...
10/23/2022
IO Learning

Subscribe

IO Learning Newsletter

News

News
Novel Endovascular Robotic Surgical System Reaches Midpoint of Pivotal Clinical Trial
09/20/2024
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY®...
09/20/2024
IO Learning
News
Histotripsy Demonstrates Technical Success, Safety for Primary and Metastatic Liver Tumors
09/04/2024
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the...
09/04/2024
IO Learning
News
Sorafenib Plus Transarterial Chemoembolization Improves Survival Outcomes, Response Among Patients With Recurrent Hepatocellular Carcinoma
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
Manageable Safety Across Treatment Periods for Durvalumab, Bevacizumab, and TACE Regimen Among Patients With Unresectable Hepatocellular Carcinoma
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
Transit Scientific Announces First Worldwide Case Performed with Innovative Embolic-Delivery Microcatheter
07/09/2024
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press...
07/09/2024
Vascular Disease Management
Imaging Systems
University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients
05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance...
05/08/2024
Cath Lab Digest
News
Histotripsy Treatment for Primary and Metastatic Liver Tumors
04/25/2024
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
First-of-Its-Kind Surgical Foam Technology Improves Operating Room Workflow
04/24/2024

Syntervention Press Release

Syntervention Press Release
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina,...
04/24/2024
EP Lab Digest
News
Fluidx Medical Reveals New Embolic Platform for Internal Bleeding, Tumor Treatment, and Other Uses
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use